Tempest to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting

14 Mar 2023
www.biospace.com
Phase 1AACR
BRISBANE, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that two abstracts have been accepted for poster presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting taking place April 14-19, 2023 in Orlando, FL. The presentations will highlight biomarker data from the Phase 1 trial of TPST-1120, an oral selective PPAR⍺ antagonist and preclinical data from TREX1 inhibitor, a tumor-selective STING pathway activatorSTING pathway activator. Poster presentation details: Title: Lipid and immune-based biomarkers associated with clinical response to TPST-1120: A small molecule antagonist of peroxisome-proliferator activated receptor-alpha Session Category: Clinical Research Excluding Trials Session Title: Biomarkers of Therapeutic Benefit 2 Session Date & Time: Monday, April 17, 2023 9:00 a.m. - 12:30 p.m. ET Location: Poster Section 39 Abstract Number: 2130 Title: Generation of novel potent human TREX1 inhibitorsTREX1 inhibitors facilitated by crystallography Session Category: Experimental and Molecular Therapeutics Session Title: Novel Antitumor Agents 3 Session Date & Time: Monday, April 17, 2023 9:00 a.m. - 12:30 p.m. ET Location: Poster Section 17 Abstract Number: 1636 ___________________________ 1 If approved by the FDA Abstracts are available for viewing via the AACR Online Itinerary Planner located here, . About Tempest Therapeutics Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both tumor-targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. The company has a diverse portfolio of novel programs ranging from early research to investigation in a randomized global study in first-line cancer patients. The company’s two novel clinical programs TPST-1120 and TPST-1495, target of PPARα and EP2/EP4, respectively, are advancing through trials designed to study the agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally available inhibitor of TREX1, a target that controls activation of the cGAS/STING pathway. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company’s website at . Investor Contacts: Sylvia Wheeler Wheelhouse Life Science Advisors swheeler@wheelhouselsa.com Aljanae Reynolds Wheelhouse Life Science Advisors areynolds@wheelhouselsa.com
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.